ALCAftadine: A topical antihistamine for use in allergic conjunctivitis

Drugs of Today

Volumn 47, Issue 12, 2011, Pages 883-890

  Namdar, Rocsanna ^a   Valdez, C ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCAFTADINE; AZELASTINE; BEPOTASTINE; CYTOCHROME P450; DRUG METABOLITE; EMEDASTINE; EPINASTINE; GENERIC DRUG; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; KETOTIFEN FUMARATE; OLOPATADINE; PLACEBO; R 89674; R 90692; TEARS NATURALE; UNCLASSIFIED DRUG;

ALLERGIC CONJUNCTIVITIS; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; BINDING AFFINITY; BRONCHITIS; CHEMOSIS; CONJUNCTIVAL HYPEREMIA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG LABELING; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EYE BURNING; EYE DISEASE; EYE IRRITATION; EYE PAIN; EYE REDNESS; EYE STINGING; FOOD AND DRUG ADMINISTRATION; GLOSSODYNIA; HEADACHE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INFLUENZA; MAST CELL; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OCULAR PRURITUS; OPHTHALMOSCOPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SLIT LAMP; SYSTEMATIC REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH PAIN; TREATMENT OUTCOME; VISUAL ACUITY;

ADMINISTRATION, TOPICAL; ANIMALS; BENZAZEPINES; CONJUNCTIVITIS, ALLERGIC; DRUG INTERACTIONS; HUMANS; IMIDAZOLES; OPHTHALMIC SOLUTIONS; PRURITUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, HISTAMINE;

EID: 84856561777     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.12.1709243     Document Type: Review

References (24)

1. Abelson, M.B., Smith, L., Chapin, M. Ocular allergic disease: mechanisms, disease sub-types, treatment. Ocul Surf 2003, 1(3): 127-49. (Pubitemid 41263901)
2. Ciprandi, G., Buscaglia, S., Cerqueti, P.M., Canonica, G.W. Drug treatment of allergic conjunctivitis. A review of the evidence. Drugs 1992, 43(2): 154-76.
3. Ono, S.J., Abelson, M.B. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol 2005, 115(1): 118-22. (Pubitemid 40075430)
4. Abelson, M.B., McLaughlin, J.T., Gomes, P.J. Antihistamines in ocular allergy: are they all created equal? Curr Allergy Asthma Rep 2011, 11(3): 205-11.
5. Tinkelman, D.G., Rupp, G., Kaufman, H., Pugely, J., Schultz, N. Double-masked, paired-comparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution compared with placebo eyedrops in the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993, 38(Suppl.): 133-40. (Pubitemid 23239419)
6. Yaylali, V., Demirlenk, I., Tatlipinar, S., Ozbay, D., Esme, A., Yildirim, C., Ozden, S. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmol Scand 2003, 81(4): 378-82. (Pubitemid 36926866)
7. Discepola, M., Deschenes, J., Abelson, M. Comparison of the topical ocular antiallergic efficacy of emedastine 0.05% ophthalmic solution to ketorolac 0.5% ophthalmic solution in a clinical model of allergic conjunctivitis. Acta Ophthalmol Scand Suppl 1999(228): 43-6. (Pubitemid 29196905)
8. Sharif, N.A., Xu, S.X., Yanni, J.M. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J Ocul Pharmacol Ther 1996, 12(4): 401-7. (Pubitemid 26405744)
9. Abelson, M.B., Welch, D.L. An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model. Acta Ophthalmol Scand Suppl 2000(230): 60-3.
10. Spangler, D.L., Abelson, M.B., Ober, A., Gotnes, P.J. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models. Clin Ther 2003, 25(8): 2245-67. (Pubitemid 37076317)
11. Crampton, H.J. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial. Clin Ther 2003, 25(7): 1975-87. (Pubitemid 36936592)
12. Ono, S.J., Lane, K. Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis. Drug Des Devel Ther 2011, 5: 77-84.
13. Bohets, H., McGowan, C., Mannens, G., Schroeder, N., Edwards-Swanson, K., Shapiro, A. Clinical pharmacology of alcaftadine, a novel antihistamine for the prevention of allergic conjunctivitis. J Ocul Pharmacol Ther 2011, 27(2): 187-95.
14. Engelhardt, H., Smits, R.A., Leurs, R., Haaksma, E., de Esch, I.J. A new generation of anti-histamines: Histamine H4 receptor antagonists on their way to the clinic. Curr Opin Drug Discov Devel 2009, 12(5): 628-43.
15. Saravanan, C., Bharti, S.K., Jaggi, S., Singh, S.K. Histamine H receptor: a novel target for inflammation therapy. Mini Rev Med Chem 2011, 11(2): 143-58.
16. Leite-de-Moraes, M.C., Diem, S., Michel, M.L., Ohtsu, H., Thurmond, R.L., Schneider, E., Dy, M. Cutting edge: histamine receptor H4 activation positively regulates in vivo IL-4 and IFN-gamma production by invariant NKT cells. J Immunol 2009, 182(3): 1233-6.
17. Ling, P., Ngo, K., Nguyen, S., Thurmond, R.L., Edwards, J.P., Karlsson, L., Fung-Leung, W.P. Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation. Br J Pharmacol 2004, 142(1): 161-71. (Pubitemid 38698205)
18. Zhang, Y., Food and Drug Administration. Alcaftadine clinical pharmacology review, NDA 22-134. http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/DevelopmentResources/UCM223817.pdf. Accessed August 8, 2011.
19. Nesbitt, M.P., Food and Drug Administration. Alcaftadine ophthalmic solution 0.25% clinical review, NDA 22-134. http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/DevelopmentResources/UCM223816.pdf. Accessed August 8, 2011.
20. Product information. Lastacaft™ (alcaftadine) [Revised 9/2011]. Allergan, Inc., http://www.allergan.com/assets/pdf/lastacaft-pi.pdf. Accessed November 28, 2011.
21. Greiner, J.V., Edwards-Swanson, K., Ingerman, A. Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%. Clin Ophthalmol 2011, 5: 87-93.
22. Torkildsen, G., Shedden, A. The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis. Curr Med Res Opin 2011, 27(3): 623-31.
23. Abelson, M.B., Chambers, W.A., Smith, L.M. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol 1990, 108(1): 84-8. (Pubitemid 20031417)
24. Alcaftadine (Lastacaft) for allergic conjunctivitis. Med Lett Drugs Ther 2011, 53(1359): 19-20.